Pharmaceuticals Acquisitions in North Carolina

Intas Pharmaceuticals, via its U.S. specialty division Accord BioPharma, completed the acquisition of the UDENYCA (pegfilgrastim-cbqv) franchise from Coherus BioSciences. The asset sale expands Accord/Intas' FDA-approved biosimilar portfolio—particularly in oncology supportive care—and brings key Coherus commercial and manufacturing personnel into Accord to support continuity and growth in the U.S. and international markets.

Swiss eye-care leader Alcon has acquired Aerie Pharmaceuticals, a Durham, North Carolina-based ophthalmic pharmaceutical company, adding commercial products Rocklatan and Rhopressa as well as a clinical-stage pipeline including AR-15512. The acquisition strengthens Alcon's ophthalmic pharmaceutical capabilities and R&D expertise and is intended to expand distribution and accelerate development of Aerie's portfolio.

Xcovery Holdings, an oncology-focused biopharmaceutical company, has acquired a majority and controlling stake in Meryx, Inc., a clinical-stage immuno-oncology company based in Chapel Hill, North Carolina. The deal aims to accelerate Meryx's clinical and preclinical drug development programs for small-molecule oncology therapies, with strategic support noted from Betta Pharmaceuticals; financial terms were not disclosed.

ADDvise Group AB has entered into a share purchase agreement to acquire all outstanding shares of Medisuite, LLC, an online pharmacy based in Cary, North Carolina that specializes in men's health medications. The purchase price is approximately USD 10.3 million (combination of cash, a promissory note and potential earn-outs); closing is expected in August 2021 and the acquisition is financed with ADDvise's own funds.

Alcami Corporation has acquired TriPharm Services, a new sterile fill‑finish manufacturing center near Research Triangle Park, North Carolina. Funds affiliated with Alcami majority owner Madison Dearborn Partners made an additional equity investment to support Alcami's growth plan, while Ampersand Capital Partners rolled a portion of its TriPharm ownership into Alcami.

Great Point Partners completed a growth recapitalization of Raleigh-based Tergus Pharma to fund construction of a new 100,000 square-foot commercial manufacturing facility for topical dermatology pharmaceuticals. The investment will expand Tergus' clinical and commercial manufacturing capacity and enable the company to offer end-to-end formulation, testing, and manufacturing services.

UK-based CDMO Sterling Pharma Solutions, a portfolio company of GHO Capital, has acquired the CiVentiChem US facility in Cary, North Carolina to establish a local presence for its North American clients and expand its chemistry development and kilo-scale cGMP capabilities. The acquisition supports Sterling’s strategy to build a global chemistry services business and follows GHO Capital’s majority investment in Sterling earlier this year.

Midatech Pharma PLC entered into a merger agreement to acquire DARA BioSciences, with DARA shareholders receiving Midatech ordinary shares via ADRs and a contingent value right (CVR). The deal gives Midatech a U.S. commercial footprint and an expanded oncology supportive-care portfolio; closing was expected in Q3/Q4 2015 subject to customary conditions and ADR listing.